Scientists Identify a Potential New Treatment for Osteoporosis

By Eric Sauter and Mika Ono

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new therapeutic approach that, while still preliminary, could promote the development of new bone-forming cells in patients suffering from bone loss.

The study, published recently by the journal Nature Communications, focused on a protein called PPARy (known as the master regulator of fat) and its impact on the fate of stem cells derived from bone marrow (“mesenchymal stem cells”). Since these mesenchymal stem cells can develop into several different cell types—including fat, connective tissues, bone and cartilage—they have a number of potentially important therapeutic applications.

The scientists knew that a partial loss of PPARy in a genetically modified mouse model led to increased bone formation. To see if they could mimic that effect using a drug candidate, the researchers combined a variety of structural biology approaches to rationally design a new compound that could repress the biological activity of PPARy.

The results showed that when human mesenchymal stem cells were treated with the new compound, which they called SR2595 (SR=Scripps Research), there was a statistically significant increase in osteoblast formation, a cell type known to form bone.  

“These findings demonstrate for the first time a new therapeutic application for drugs targeting PPARy, which has been the focus of efforts to develop insulin sensitizers to treat type 2 diabetes,” said Patrick Griffin, chair of the Department of Molecular Therapeutics and director of the Translational Research Institute at Scripps Florida. “We have already demonstrated SR2595 has suitable properties for testing in mice; the next step is to perform an in-depth analysis of the drug’s efficacy in animal models of bone loss, aging, obesity and diabetes.”

In addition to identifying a potential new therapeutic for bone loss, the study may have even broader implications.

“Because PPARG is so closely related to several proteins with known roles in disease, we can potentially apply these structural insights to design new compounds for a variety of therapeutic applications,” said David P. Marciano, first author of the study, a recent graduate of TSRI’s PhD program and former member of the Griffin lab. “In addition, we now better understand how natural molecules in our bodies regulate metabolic and bone homeostasis, and how unwanted changes can underlie the pathogenesis of a disease.” Marciano will focus on this subject in his postdoctoral work in the Department of Genetics at Stanford University.

In addition to Marciano and Griffin, other authors of the study, “Pharmacological Repression of PPARγ Promotes Osteogenesis,” are Dana S. Kuruvilla, Siddaraju V. Boregowda, Alice Asteian, Travis S. Hughes, Ruben D. Garcia-Ordonez, Scott J. Novick, Cesar A. Corzo, Tanya M. Khan, Douglas J. Kojetin, Donald G. Phinney and Theodore M. Kamenecka of TSRI; and John B. Bruning of The University of Adelaide (Australia). See http://www.nature.com/ncomms/2015/150612/ncomms8443/abs/ncomms8443.html

The work was supported by the National Institutes of Health (grants DK08026, MH084512, OD018254-01, DK097890, DK103116 and DK101871).

Send comments to: press[at]scripps.edu